How to approach castration-resistant prostate cancer?

Abstract

The therapeutic landscape of castration-resistant prostate cancer (CRPC) has changed dramatically in the last decade. Previously, limited to castration, second-line hormonal manipulations, and palliative treatment with mitoxantrone plus prednisone, median overall survival (OS) remained in the 9-18 months range. With multiple lines of survival improving chemotherapies, AR-directed drugs, as well as new immunotherapy and bone-directed therapies, median OS increased to more than 30 months and quality of life increased accordingly. The question remains, as how to sequence, and choose the best therapeutic option for each individual patient with the current data.

Proceedings in oncology: Aren’t we back to the future?

“…Sefik Igdem and Sevil Bavbek summarized the recent advances in hypofractionated radiotherapy for local and management of castrate-resistant prostate cancer [4,5].…”